Duration of Safe Fasting on Dapagliflozin
Patients on dapagliflozin should withhold the medication for at least 3 days prior to any major surgery or procedures involving prolonged fasting, and the drug should only be resumed once the patient is clinically stable and has resumed oral intake. 1
Key Recommendation from FDA Labeling
The FDA-approved prescribing information explicitly states that dapagliflozin must be withheld for at least 3 days before major surgery or procedures associated with prolonged fasting 1. This is a critical safety measure to mitigate the risk of diabetic ketoacidosis (DKA), which can occur even with normal or near-normal blood glucose levels (euglycemic DKA).
Why This Matters: The DKA Risk
Prolonged fasting is a known precipitating factor for ketoacidosis in patients taking SGLT2 inhibitors. The mechanism involves:
- Reduced caloric intake combined with continued urinary glucose excretion
- Relative insulin deficiency during fasting states
- Continued drug effect even after discontinuation (urinary glucose excretion persists for 3 days after stopping dapagliflozin) 1
The 2025 ADA guidelines specifically warn about DKA risk with SGLT2 inhibitors during prolonged fasting and recommend discontinuation 3-4 days before scheduled surgery 2.
Clinical Considerations for Different Fasting Scenarios
Planned Fasting (Surgery/Procedures)
- Stop dapagliflozin at least 3 days before the procedure 1
- Resume only when patient is clinically stable and eating normally
- Monitor for signs of ketoacidosis regardless of blood glucose levels
Unplanned Fasting (Acute Illness)
- Discontinue dapagliflozin immediately if the patient cannot maintain oral intake
- Consider ketone monitoring, especially if the patient has risk factors (type 1 diabetes, history of pancreatitis, reduced insulin doses) 1
- Assess for ketoacidosis even if blood glucose appears normal (<250 mg/dL)
Religious/Intermittent Fasting
While not explicitly addressed in the labeling, the same principles apply: fasting periods exceeding 24-48 hours warrant serious consideration of temporarily holding dapagliflozin, given the cumulative risk of ketosis with prolonged caloric restriction.
Warning Signs During Fasting
Patients and providers must watch for ketoacidosis symptoms, which include:
- Nausea, vomiting, abdominal pain
- Generalized malaise and shortness of breath
- Dehydration signs
Critical pitfall: These symptoms can occur with blood glucose levels below typical DKA thresholds (<250 mg/dL), making diagnosis challenging 1.
Additional Safety Considerations
The ADA guidelines emphasize "sick-day planning" for SGLT2 inhibitors 2. This includes:
- Patient education about when to stop the medication
- Attention to volume status (dapagliflozin increases risk of volume depletion during fasting)
- Monitoring kidney function, as fasting combined with volume depletion can worsen renal function
Volume depletion is particularly concerning in elderly patients, those on diuretics, or those with baseline renal impairment 1.
Practical Algorithm
- Planned fasting >24 hours: Stop dapagliflozin ≥3 days before
- Acute illness with inability to eat: Stop immediately
- Resume criteria: Patient eating normally AND clinically stable AND no signs of ketosis
- If ketoacidosis suspected: Stop drug, check ketones, treat promptly before considering restart 1